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Gene therapy represents a promising therapeutic option for many inherited and acquired retinal diseases. Recombinant adeno-asso-
ciated viral vectors (AAV) are the most eﬃcient tools to transfer genes in vivo to the retina. The recent identiﬁcation of dozens of novel
AAV serotypes enormously expands on the versatility of AAV as vector system for in vivo somatic gene transfer. The results from the
forthcoming trials with AAV in the retina of patients with Leber Congenital Amaurosis will be critical for the rapid development of
AAV-based therapeutics for retinal diseases.
 2007 Elsevier Ltd. All rights reserved.
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Adeno-associated viruses (AAVs) belong to the Parvo-
viridae family. These non-human pathogens possess a lin-
ear, single-stranded DNA genome that can replicate in
the presence of diﬀerent helper viruses such as adenovirus,
herpes virus or papilloma virus (Muzyczka, 2001). AAVs
were originally isolated as contaminants from laboratory
stocks of adenoviruses.
The AAV genome (4.7 kb) consists of two open reading
frames, rep, required for viral genome replication; and cap,
encoding AAV structural proteins, rep and cap DNA
sequences are enclosed within two symmetric T shaped pal-
indromic terminal sequences called inverted terminal
repeats (ITRs) (Muzyczka, 2001). Recombinant vectors
are generated by deleting the rep and cap sequences from
the genome and by inserting the therapeutic gene of interest
between the ITRs.
AAV vectors are particularly advantageous for gene
transfer because of their ability to transduce non-dividing0042-6989/$ - see front matter  2007 Elsevier Ltd. All rights reserved.
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E-mail address: auricchio@tigem.it (A. Auricchio).cells, and the possibility of a long and sustained levels of
therapeutic gene expression. Since the generation of the
ﬁrst recombinant AAV2 vector (Hermonat & Muzyczka,
1984; Tratschin, West, Sandbank, & Carter, 1984), 108
novel capsid sequences have been isolated (from 55 human
and 53 non-human primates), and some of them were used
to generate novel vectors for gene transfer (Chiorini, Kim,
Yang, & Kotin, 1999; Chiorini, Yang, Liu, Safer, & Kotin,
1997; Gao et al., 2002; Gao et al., 2004; Gao, Vandenber-
ghe, & Wilson, 2005; Rutledge, Halbert, & Russell, 1998;
Xiao et al., 1999). Recombinant vectors can be generated
using both capsid proteins and genomes from the same
serotype or the vector genome can be derived from
AAV2, and included in the capsid from an alternative
AAV serotype (Fig. 1) (Chao et al., 2000; Hildinger
et al., 2001). This allows to assess the net contribution of
the capsid proteins to vector transduction. Exchanging
capsids among various AAV serotypes is eﬀective for con-
ferring speciﬁc cellular tropism and intensity as well as
onset of gene expression (Fig. 1). For example, AAV 2/1
(Gregorevic et al., 2004; Rabinowitz et al., 2002), 2/7
(Gao et al., 2002), 2/8 (Wang et al., 2005) and 2/9 (Inagaki
et al., 2006; Pacak et al., 2006) (where the ﬁrst number
deﬁnes the vector genome and the second the capsid) eﬃ-
ciently transduce muscle and heart by either direct or sys-
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Fig. 1. Generation of recombinant vectors based on diﬀerent AAV serotypes. Transfection in the packaging cells of the plasmids containing: the AAV
genome (with the therapeutic gene contained between the viral inverted terminal repeats, ITRs) and the packaging sequences (the cap genes encoding for
the capsids and the rep open reading frames belonging to serotype 2 to allow the most eﬃcient packaging of a viral genome with AAV2 ITRs) results in
production of recombinant virions. The hybrid virions containing the genome of one serotype (i.e. AAV2) and a diﬀerent capsid (AAV2/1–9) have tropism
dependent on the capsid sequence.
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larly amenable for liver-directed gene transfer (Gao et al.,
2002; Inagaki et al., 2006), while AAV 2/1 (Burger et al.,
2004; Passini et al., 2003), 2/4 (Liu, Martins, Chiorini, &
Davidson, 2005), 2/5 (Burger et al., 2004; Mastakov, Baer,
Kotin, & During, 2002), 2/9 and Rh10 (Cearley & Wolfe,
2006) can transduce diﬀerent cells of the central nervous
system (CNS). In addition, AAV2/6 (Halbert, Allen, &
Miller, 2001), 2/5 (Auricchio, O’Connor, et al., 2002; Zab-
ner et al., 2000) and 2/9 (Limberis & Wilson, 2006) eﬃ-
ciently transfer genes to conducting airway as well as
alveolar cells. Onset of gene expression is also capsid
dependent as vectors with AAV5 or 1 capsids have detect-
able levels of transgene expression within days following
subretinal administration while AAV2/2 vectors require
weeks to achieve the same levels of gene expression (Auric-
chio et al., 2001). The combination of speciﬁcity and eﬃ-
ciency of in vivo gene transfer derived from the use of the
various AAV serotypes has allowed the development of
novel therapeutic options for inherited and acquired
human diseases.
2. Recombinant AAV vectors in the retina
The structure and accessibility of the retina makes it an
ideal target organ for genetic therapies (Allocca, Tessitore,
Cotugno, & Auricchio, 2006; Auricchio & Rolling, 2005;
Bennett & Maguire, 2000). The partial immune privileged
properties of the eye can limit immune responses toward
the transgene and the vector. In addition, the eye is
enclosed and the presence of the blood–retinal-barrier
can help avoiding unintentional spreading of vectors to
neighboring tissues as well as to the general circulation.Retinal diseases are transmitted as monogenic or com-
plex traits. In the last two decades over 130 genes have been
identiﬁed that cause retinal diseases (Retinal Information
Network: www.sph.uth.tmc.edu/Retnet/), and a number
of small and large animal models that exist faithfully reca-
pitulate the human pathologies, allowing for the testing of
novel treatments.
Inherited retinal degenerations such as retinitis pigmen-
tosa (RP) or Leber Congenital Amaurosis (LCA) (Cremers,
van den Hurk, & den Hollander, 2002; Dryja, 2001; Kap-
lan, Perrault, & Unnich, 2000) are caused by mutations in
genes primarily expressed in photoreceptors or the retinal
pigment epithelium (RPE). RP and LCA are characterized
by extreme genotypic and phenotypic heterogeneity, vari-
ous patterns of Mendelian inheritance and primary and sec-
ondary cell involvement (Dryja, 2001; Kaplan et al., 2000).
Common retinal diseases inherited as complex traits are
age-related macular degeneration (AMD), proliferative dia-
betic retinopathy and retinopathy of prematurity (ROP),
which in their severe forms are characterized by ocular neo-
vascularization. The unbalance between pro- and anti-
angiogenetic molecules in favor of the former is the ﬁnal
common pathogenetic stimulus that triggers the formation
of aberrant vessels, eventually leading to blindness in ocular
neovascular diseases (Das & McGuire, 2003; Tuo, Boja-
nowski, & Chan, 2004). Finally, glaucoma is a common ret-
inal blinding disease characterized by increased intraocular
pressure which independently of its monogenic or multifac-
torial inheritance is associated with retinal ganglion cells
apoptosis (Sheﬃeld & Alward, 2000).
The typical approaches employed to correct retinal dis-
eases caused by recessive or dominant mutations are based
on gene replacement or gene inactivation, respectively
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rar, Kenna, & Humphries, 2002; Wilson & Wensel,
2003). In both cases the therapeutic nucleic acids need to
be targeted to the cells that are primarily aﬀected by the
mutation (i.e. the RPE or photoreceptors). In addition, a
generic strategy to delay retinal degeneration or the glau-
coma-associated retinal ganglion cell apoptosis has been
developed using gene delivery of secretable anti-apoptotic
factors or survival factors (Bainbridge, Tan, & Ali, 2006;
Borras, Brandt, Nickells, & Ritch, 2002; Surace & Auric-
chio, 2003). Viral-mediated gene delivery of secreted thera-
peutic proteins has additionally been used to provide
symptomatic treatments for those retinal diseases that are
characterized by ocular neovascularization. Animal models
of AMD and ROP have been successfully treated with
AAV vectors encoding for secretable anti-angiogenic mol-
ecules (Bainbridge et al., 2003; Campochiaro, 2007). The
use of soluble molecules in anti-angiogenic and neurotro-
phic therapy overcomes the problem of speciﬁcally target-
ing aﬀected cells, since the therapeutic protein produced
by ‘‘factory cells’’ can diﬀuse across the retina into ocular
ﬂuids (Auricchio, 2003).
Regardless of the retinal disease target and the therapeu-
tic strategy, aspects that are critical to the eﬃcacy of gene-
based therapies include: (i) route and timing of gene trans-
fer, (ii) eﬃciency and speciﬁcity of retinal cell transduction,
and (iii) transcriptional regulation of pattern, time and lev-
els of transgene expression.
2.1. Route and timing of gene transfer
The routes of vector administration to the retina deter-
mine which cells are exposed to the therapeutic agent.
The subretinal approach is typically used for treatment of
inherited retinal diseases aﬀecting photoreceptors or
RPE. The subretinal administration of AAV vectors results
in the transduction of both photoreceptors and RPE cells
(Surace & Auricchio, 2003). AAV vectors have been suc-
cessfully used to treat small and large animal models with
RPE-speciﬁc genetic defects including those causing muco-
polysaccharidosis VI (Ho et al., 2002) and VII (Hennig
et al., 2004), RP due to a MERTK deﬁciency (Smith
et al., 2003), LCA due to an RPE65 gene deﬁciency
(Acland et al., 2005; Acland et al., 2001; Dejneka et al.,
2004; Jacobson et al., 2006; LeMeur et al., 2007; Narfstrom
et al., 2003; Pang et al., 2006) and Ocular Albinism due to
OA1 deﬁciency (Surace et al., 2005). Gene transfer
approaches for correction of photoreceptor-speciﬁc dis-
eases with subretinal injection of AAV vectors were suc-
cessfully used to recover photoreceptor function in
murine models carrying null mutations for the rpgrip (Paw-
lyk et al., 2005) and rs1h genes (Min et al., 2005; Zeng
et al., 2004). Because the subretinal space is near to the
choroidal vascular plexus, subretinal administration of
AAV vectors encoding for anti-angiogenic factors was also
used to treat choroidal neovascularization (Lai et al., 2001;
Mori et al., 2002).The other route of vector administration is the intravi-
treal injection, which exposes the inner retina to the thera-
peutic agent. This route of administration was used to treat
optic neuritis in rodents (Guy, Qi, & Hauswirth, 1998; Qi,
Hauswirth, & Guy, 2007), to protect retinal ganglion cells
(RGC) in rat models of glaucoma (Martin & Quigley,
2004; McKinnon et al., 2002; Renwick et al., 2006; Zhou,
Pernet, Hauswirth, & Di Polo, 2005) and to treat models
of retinal neovascularization (Auricchio et al., 2002; Bain-
bridge et al., 2002; Lai et al., 2005; Raisler, Berns, Grant,
Beliaev, & Hauswirth, 2002).
An additional factor playing a critical role in viral-med-
iated retinal transduction is the time of gene delivery. Ret-
inal degeneration varies from early and severe to late and
progressive. Slowly progressive diseases have a much wider
therapeutic window than those with an earlier onset such as
LCA2. Timely gene delivery in early onset and congenital
retinal dystrophies may prevent the pathological conse-
quences of the mutation to retinal function. Administra-
tion of AAVs with reporter or therapeutic genes to the
fetal or the newborn murine retina results in robust trans-
gene expression and recovery of retinal pathology in both
models of retinal degeneration and neovascularization
(Auricchio et al., 2002; Bainbridge et al., 2002; Dejneka
et al., 2004; Lai et al., 2005; Raisler et al., 2002; Surace
et al., 2003).
2.2. Eﬃciency and speciﬁcity of retinal cell transduction
To be eﬀective, gene therapy to the retina initially
requires eﬃcient, speciﬁc and widely distributed transduc-
tion of virus to target cells. Once this is achieved, it is pos-
sible to tailor gene expression to appropriate levels and
spatial patterns through the use of speciﬁc promoter ele-
ments. Therefore, the main limiting step in the process is
the targeted transduction mediated by AAV. This includes:
vector binding to a speciﬁc receptor and entry into the tar-
get cell; intracellular traﬃcking to the nucleus; AAV
decapsidation and conversion of its single-strand genome
into a DNA duplex; transgene expression (Rabinowitz &
Samulski, 2000). The ﬁrst AAV serotype tested into the ret-
ina was AAV2/2 (Ali et al., 1996). The subretinal adminis-
tration of this serotype results in the transduction of both
photoreceptors and RPE cells, with an onset of transgene
expression that peaks at 4 weeks after vector administra-
tion (Ali et al., 1996; Auricchio et al., 2001; Bennett, Duan,
Engelhardt, & Maguire, 1997; Flannery et al., 1997; Rabi-
nowitz & Samulski, 2002; Rolling et al., 2000; Rolling
et al., 1999; Sarra et al., 2002). Intravitreal administration
of AAV2/2 results in transduction of ganglion cells, trabec-
ular meshwork cells and various cells of the inner nuclear
layer, including Mu¨ller cells (Ali et al., 1998; Auricchio
et al., 2001; Borras et al., 2006; Liang et al., 2001; Martin,
Klein, & Quigley, 2002). The availability of AAV vectors
derived from diﬀerent serotypes has enormously enhanced
AAV transduction eﬃciency and speciﬁcity (Auricchio
et al., 2001; Rabinowitz et al., 2002; Yang et al., 2002).
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or 2/4 vectors, robust expression of the EGFP reporter
gene is observed in the RPE of mice, dogs and non-human
primates (NHP) (Auricchio et al., 2001; Rabinowitz et al.,
2002; Weber et al., 2003; Yang et al., 2002). Subretinal
administration of AAV5/5 (where both genome and caps-
ids belong to AAV5) or AAV2/5 also results in early
RPE transduction, but more importantly, in robust expres-
sion in photoreceptors which is higher than that obtained
with AAV2/2. (Auricchio et al., 2001; Lotery et al., 2003;
Yang et al., 2002) (Fig. 2). Notably, intravitreal injection
of AAV2/1 and 2/5 resulted in poor transduction of the
inner retina (Auricchio et al., 2001). More recently large
numbers of novel AAV capsid sequences have been iso-
lated (see above) and some of these were used for the gen-
eration of novel AAV vectors, potentially allowing for
further expansion of AAV retinal tropism and transduction
(Fig. 1). Based on the ability of AAV2/7, 2/8, and 2/9 to
transduce various tissues (Cearley & Wolfe, 2006; Gao
et al., 2002; Inagaki et al., 2006; Pacak et al., 2006), we
recently tested their transduction characteristics in the mur-
ine retina. Subretinal delivery of AAV2/7 (Fig. 2), 2/8, or
2/9 (data not shown) vectors encoding EGFP, resulted in
eﬃcient transduction of both RPE and photoreceptor cells.
The ability of AAV2/7 and 2/8, as well as of AAV2/5 (to
date considered the best vector for photoreceptor transduc-
tion) to eﬃciently and rapidly transduce murine photore-
ceptors may have a signiﬁcant impact on developing
therapies for severe inherited photoreceptor diseases. To
this end, gene replacement with AAV2/2 vectors in the
rdl and rds murine models (due to deﬁciency in the pde6b
and peripherin genes, respectively) resulted in low levels
of photoreceptor transduction and in lack of rescue or in
short-lived rescue (Ali et al., 2000; Jomary, Vincent, Grist,
Neal, & Jones, 1997; Sarra et al., 2001; Schlichtenbrede
et al., 2003).
2.3. Transcriptional regulation of pattern, time and levels of
transgene expression
In inherited retinal diseases, stable expression of the
therapeutic gene is required at appropriate levels and
should be restricted to the cells in which the mutationFig. 2. Fluorescence microscopy analysis of EGFP expression four weeks post-
2/7-CMV-EGFP (central and right panel panels). The use of diﬀerent AAV vec
and cellular speciﬁcities. RPE, retinal pigment epithelium; ONL, outer nucleaexerts its detrimental eﬀect. Conversely, in diseases such
as retinal neovascularization, both levels and timing of
transgene expression should be regulated. Tissue-speciﬁc
promoters for RPE restricted gene expression include pro-
moter fragments from the RPE65, VMD2, and OA1 genes
(Acland et al., 2005; Dinculescu et al., 2005; Vetrini et al.,
2004). The proximal promoter region of the rod opsin
gene (RPPR) is used for photoreceptor-speciﬁc expression
(Flannery et al., 1997; Glushakova et al., 2006). As shown
in Fig. 2, subretinal administration of an AAV2/5 encod-
ing EGFP under the control of the ubiquitous CMV pro-
moter results in expression in both RPE and
photoreceptor cells, while the same AAV serotype harbor-
ing the RPPR promoter restricts EGFP expression to
photoreceptors.
Systems to regulate the timing and levels of gene expres-
sion have been developed to obtain therapeutic eﬃcacy and
avoid toxicity. For this purpose transcription factors have
been engineered that are regulated either positively or neg-
atively by small molecule drags (Clackson, 2000). Two
inducible systems have been tested in the murine and
NHP retina transduced with AAV vectors. One is based
on the ability of rapamycin to reconstitute a functional
transcription factor that binds to a promoter element
upstream of the target gene (Pollock et al., 2000; Rivera
et al., 1996). Subretinal administration of AAV containing
the regulated system followed by systemic administration
of rapamycin result in expression of the target gene that
is drug-dependent in time and levels (Auricchio, Rivera,
et al., 2002; Lebherz et al., 2005). Similar results have been
obtained using the tetracycline (tet)-inducibile system, in
which an activator or silencer (tetON or tetOFF, respec-
tively) vector and an inducible doxycycline (dox)-respon-
sive vector were subretinally injected in rats and NHP
(Dejneka et al., 2001; Folliot et al., 2003; McGee Sanftner,
Rendahl, & Quiroz, 2001; Smith et al., 2005; Stieger et al.,
2006).
In conclusion, the versatility, eﬃcacy and safety of AAV
vectors for retinal gene transfer have been successfully
determinate in animal models. AAV safety and eﬃcacy is
being tested in patients with LCA2 due to RPE65 muta-
tions (http://www.blindness.org; Bennett, 2006). This may
allow to treat many additional retinal diseases.subretinal injection of AAV2/5-RHO-EGFP (left panel) and AAV2/5- and
tor serotypes and promoters have distinct retinal transduction eﬃciencies
r layer; INL, inner nuclear layer; GCL, ganglion cell layer.
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